Advisory Committees; Tentative Schedule of Meetings for 2013, 104-105 [2012-31475]

Download as PDF 104 Federal Register / Vol. 78, No. 1 / Wednesday, January 2, 2013 / Notices will be posted to the docket at https:// www.regulations.gov. Dated: December 26, 2012. Leslie Kux, Assistant Commissioner for Policy. [FR Doc. 2012–31478 Filed 12–31–12; 8:45 am] BILLING CODE 4160–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2012–N–0001] Advisory Committees; Tentative Schedule of Meetings for 2013 AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) is announcing a tentative schedule of forthcoming meetings of its public advisory committees for 2013. During 1991, at the request of the Commissioner of Food and Drugs (the Commissioner), the SUMMARY: Institute of Medicine (the IOM) conducted a study of the use of FDA’s advisory committees. In its final report, one of the IOM’s recommendations was for the Agency to publish an annual tentative schedule of its meetings in the Federal Register. This publication implements the IOM’s recommendation. FOR FURTHER INFORMATION CONTACT: Teresa L. Hays, Advisory Committee Oversight and Management Staff (HF– 4), Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 5290, Silver Spring, MD 20993, 301–796–8220. SUPPLEMENTARY INFORMATION: The IOM, at the request of the Commissioner, undertook a study of the use of FDA’s advisory committees. In its final report in 1992, one of the IOM’s recommendations was for FDA to adopt a policy of publishing an advance yearly schedule of its upcoming public advisory committee meetings in the Federal Register; FDA has implemented this recommendation. The annual publication of tentatively scheduled advisory committee meetings will provide both advisory committee members and the public with the opportunity, in advance, to schedule attendance at FDA’s upcoming advisory committee meetings. Because the schedule is tentative, amendments to this notice will not be published in the Federal Register. However, changes to the schedule will be posted on the FDA advisory committees’ Internet site located at https://www.fda.gov/ AdvisoryCommittees/default.htm. FDA will continue to publish a Federal Register notice 15 days in advance of each upcoming advisory committee meeting, to announce the meeting (21 CFR 14.20). The following list announces FDA’s tentatively scheduled advisory committee meetings for 2013. You may also obtain up-to-date information by calling the Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area) or on the FDA Internet Web site under our 2013 tentative scheduled meeting listing at https://www.fda.gov/ AdvisoryCommittees/Calendar/ ucm153468.htm. TABLE 1 Committee name Tentative date(s) of meeting(s) OFFICE OF THE COMMISSIONER Pediatric Advisory Committee .................................................................. Risk Communication Advisory Committee ............................................... Science Board to FDA .............................................................................. March 14–15, September 19–20. February 11–12, April 29–30, August 15–16, December 16–17. February 27, June 24, November 20. CENTER FOR BIOLOGICS EVALUATION AND RESEARCH Allergenic Products Advisory Committee ................................................. Blood Products Advisory Committee ........................................................ Cellular, Tissue and Gene Therapies Advisory Committee ..................... Transmissible Spongiform Encephalopathies Advisory Committee ......... Vaccines and Related Biological Products Advisory Committee ............. November 5–6. February 12–13, April 8–9, August 1–2. January 15, April 17–18, June 27–28, October 24–25. March 14–15. February 27, May 8–9 or July 17–18 (Backup date), September 18–19, November 13–14. tkelley on DSK3SPTVN1PROD with CENTER FOR DRUG EVALUATION AND RESEARCH Anesthetic and Analgesic Drug Products Advisory Committee ............... Anti-Infective Drugs Advisory Committee ................................................. Antiviral Drugs Advisory Committee ......................................................... Arthritis Advisory Committee .................................................................... Cardiovascular and Renal Drugs Advisory Committee ............................ Dermatologic and Ophthalmic Drugs Advisory Committee ...................... Drug Safety and Risk Management Advisory Committee ....................... Endocrinologic and Metabolic Drugs Advisory Committee ...................... Gastrointestinal Drugs Advisory Committee ............................................ Medical Imaging Drugs Advisory Committee ........................................... Nonprescription Drugs Advisory Committee ............................................ Oncologic Drugs Advisory ........................................................................ Committee ................................................................................................ Pharmacy Compounding Drugs Advisory Committee .............................. Peripheral and Central Nervous System Drugs Advisory Committee ..... Advisory Committee for Pharmaceutical Science and Clinical Pharmacology. Psychopharmacologic Drugs Advisory Committee .................................. Pulmonary-Allergy Drugs Advisory Committee ........................................ Advisory Committee for Reproductive Health Drugs ............................... VerDate Mar<15>2010 16:42 Dec 31, 2012 Jkt 229001 PO 00000 Frm 00022 Fmt 4703 Date(s), if needed, to be determined. Date(s), if needed, to be determined. May and October dates to be determined. July or August and fall dates to be determined. April 17 and other date(s) to be determined. Date(s), if needed, to be determined. January 24–25, March 5. January 10, July, and August dates to be determined. March 19 and other date(s) to be determined. February 14 and May date to be determined. Date(s), if needed, to be determined. April 5, May, June, July, September date(s) to be determined. Date(s), if needed, to be determined. May 22. Date(s), if needed, to be determined. Date(s), if needed, to be determined. January 29–30, March 7. March 4–5, July 9. Sfmt 4703 E:\FR\FM\02JAN1.SGM 02JAN1 Federal Register / Vol. 78, No. 1 / Wednesday, January 2, 2013 / Notices 105 TABLE 1—Continued Committee name Tentative date(s) of meeting(s) CENTER FOR DEVICES AND RADIOLOGICAL HEALTH Medical Devices Advisory Committee (Comprised of 18 Panels) Anesthesiology and Respiratory Therapy Devices Panel ........................ Circulatory System Devices Panel ........................................................... Clinical Chemistry and Clinical Toxicology Devices Panel ...................... Dental Products Panel .............................................................................. Ear, Nose, and Throat Devices Panel ..................................................... Gastroenterology-Urology Devices Panel ................................................ General and Plastic Surgery Devices Panel ............................................ General Hospital and Personal Use Devices Panel ................................ Hematology and Pathology Devices Panel .............................................. Immunology Devices Panel ...................................................................... Medical Devices Dispute Resolution Panel ............................................. Microbiology Devices Panel ..................................................................... Molecular and Clinical Genetics Panel .................................................... Neurological Devices Panel ..................................................................... Obstetrics and Gynecology Devices Panel .............................................. Ophthalmic Devices Panel ....................................................................... Orthopaedic and Rehabilitation Devices Panel ........................................ Radiological Devices Panel ...................................................................... Device Good Manufacturing Practice Advisory Committee ..................... National Mammography Quality Assurance Advisory Committee ........... Technical Electronic Product Radiation Safety Standards Committee .... Date(s), if needed, to be determined. May 17, May 24, June 27, September 27, November 22. April 25. Date(s), if needed, to be determined. July 12. April 24, May 16. June 13. June 28, August 30. Date(s), if needed, to be determined. Date(s), if needed, to be determined. Date(s), if needed, to be determined. June 14. September 13. February 22. September 20. June 14, August 23. April 5, September 26. September 12. April 11. October 25. Date(s), if needed, to be determined. CENTER FOR FOOD SAFETY AND APPLIED NUTRITION Food Advisory Committee ........................................................................ July 15–16, August 29–30, September 23–24. CENTER FOR TOBACCO PRODUCTS Tobacco Products Scientific Advisory Committee ................................... Feb 11–12, April 30–May 1. CENTER FOR VETERINARY MEDICINE Veterinary Medicine Advisory Committee ................................................ Date(s), if needed, to be determined. NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH (NCTR) Science Advisory Board to NCTR ............................................................ Dated: December 26, 2012. Leslie Kux, Assistant Commissioner for Policy. [FR Doc. 2012–31475 Filed 12–31–12; 8:45 am] BILLING CODE 4160–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES\ National Institutes of Health Proposed Collection; Comment Request (60-Day FRN); A Generic Submission for Formative Research, Pretesting, and Customer Satisfaction of NCI’s Communication and Education Resources (NCI) Under the provisions of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Institutes of Health (NIH) will publish periodic summaries of proposed tkelley on DSK3SPTVN1PROD with SUMMARY: VerDate Mar<15>2010 16:42 Dec 31, 2012 Jkt 229001 December 10–11. projects to be submitted to the Office of Management and Budget (OMB) for review and approval. Written comments and/or suggestions from the public and affected agencies are invited to address one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) The quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. PO 00000 Frm 00023 Fmt 4703 Sfmt 4703 To submit comments in writing, request more information on the proposed project, or to obtain a copy of the data collection plans and instruments, contact: Nina Goodman, Public Health Advisor, Office of Communications and Education (OCE), NCI, NIH, 6116 Executive Blvd., Suite 400, Rockville, MD 20892, call non-tollfree number (301) 435–7789 or email your request, including your address to: goodmann@mail.nih.gov. Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication. Proposed Collection: A Generic Submission For Formative Research, Pretesting, and Customer Satisfaction of NCI’s Communication and Education Resources, 0925–0046, Expiration Date 2/28/2013—EXTENSION—National Cancer Institute, National Institutes of Health (NIH). Need and Use of Information Collection: In order to carry out NCI’s E:\FR\FM\02JAN1.SGM 02JAN1

Agencies

[Federal Register Volume 78, Number 1 (Wednesday, January 2, 2013)]
[Notices]
[Pages 104-105]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-31475]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2012-N-0001]

Advisory Committees; Tentative Schedule of Meetings for 2013

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing a
tentative schedule of forthcoming meetings of its public advisory
committees for 2013. During 1991, at the request of the Commissioner of
Food and Drugs (the Commissioner), the Institute of Medicine (the IOM)
conducted a study of the use of FDA's advisory committees. In its final
report, one of the IOM's recommendations was for the Agency to publish
an annual tentative schedule of its meetings in the Federal Register.
This publication implements the IOM's recommendation.

FOR FURTHER INFORMATION CONTACT: Teresa L. Hays, Advisory Committee
Oversight and Management Staff (HF-4), Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 32, rm. 5290, Silver Spring, MD 20993,
301-796-8220.

SUPPLEMENTARY INFORMATION: The IOM, at the request of the Commissioner,
undertook a study of the use of FDA's advisory committees. In its final
report in 1992, one of the IOM's recommendations was for FDA to adopt a
policy of publishing an advance yearly schedule of its upcoming public
advisory committee meetings in the Federal Register; FDA has
implemented this recommendation. The annual publication of tentatively
scheduled advisory committee meetings will provide both advisory
committee members and the public with the opportunity, in advance, to
schedule attendance at FDA's upcoming advisory committee meetings.
Because the schedule is tentative, amendments to this notice will not
be published in the Federal Register. However, changes to the schedule
will be posted on the FDA advisory committees' Internet site located at
https://www.fda.gov/AdvisoryCommittees/default.htm. FDA will continue to
publish a Federal Register notice 15 days in advance of each upcoming
advisory committee meeting, to announce the meeting (21 CFR 14.20).
The following list announces FDA's tentatively scheduled advisory
committee meetings for 2013. You may also obtain up-to-date information
by calling the Advisory Committee Information Line, 1-800-741-8138
(301-443-0572 in the Washington, DC area) or on the FDA Internet Web
site under our 2013 tentative scheduled meeting listing at https://www.fda.gov/AdvisoryCommittees/Calendar/ucm153468.htm.

Table 1
------------------------------------------------------------------------
Committee name Tentative date(s) of meeting(s)
------------------------------------------------------------------------
OFFICE OF THE COMMISSIONER
------------------------------------------------------------------------
Pediatric Advisory Committee........... March 14-15, September 19-20.
Risk Communication Advisory Committee.. February 11-12, April 29-30,
August 15-16, December 16-17.
Science Board to FDA................... February 27, June 24, November
20.
------------------------------------------------------------------------
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH
------------------------------------------------------------------------
Allergenic Products Advisory Committee. November 5-6.
Blood Products Advisory Committee...... February 12-13, April 8-9,
August 1-2.
Cellular, Tissue and Gene Therapies January 15, April 17-18, June
Advisory Committee. 27-28, October 24-25.
Transmissible Spongiform March 14-15.
Encephalopathies Advisory Committee.
Vaccines and Related Biological February 27, May 8-9 or July 17-
Products Advisory Committee. 18 (Backup date), September 18-
19, November 13-14.
------------------------------------------------------------------------
CENTER FOR DRUG EVALUATION AND RESEARCH
------------------------------------------------------------------------
Anesthetic and Analgesic Drug Products Date(s), if needed, to be
Advisory Committee. determined.
Anti-Infective Drugs Advisory Committee Date(s), if needed, to be
determined.
Antiviral Drugs Advisory Committee..... May and October dates to be
determined.
Arthritis Advisory Committee........... July or August and fall dates
to be determined.
Cardiovascular and Renal Drugs Advisory April 17 and other date(s) to
Committee. be determined.
Dermatologic and Ophthalmic Drugs Date(s), if needed, to be
Advisory Committee. determined.
Drug Safety and Risk Management January 24-25, March 5.
Advisory Committee.
Endocrinologic and Metabolic Drugs January 10, July, and August
Advisory Committee. dates to be determined.
Gastrointestinal Drugs Advisory March 19 and other date(s) to
Committee. be determined.
Medical Imaging Drugs Advisory February 14 and May date to be
Committee. determined.
Nonprescription Drugs Advisory Date(s), if needed, to be
Committee. determined.
Oncologic Drugs Advisory............... April 5, May, June, July,
Committee.............................. September date(s) to be
determined.
Pharmacy Compounding Drugs Advisory Date(s), if needed, to be
Committee. determined.
Peripheral and Central Nervous System May 22.
Drugs Advisory Committee.
Advisory Committee for Pharmaceutical Date(s), if needed, to be
Science and Clinical Pharmacology. determined.
Psychopharmacologic Drugs Advisory Date(s), if needed, to be
Committee. determined.
Pulmonary[dash]Allergy Drugs Advisory January 29-30, March 7.
Committee.
Advisory Committee for Reproductive March 4-5, July 9.
Health Drugs.
------------------------------------------------------------------------

[[Page 105]]

CENTER FOR DEVICES AND RADIOLOGICAL HEALTH
------------------------------------------------------------------------
Medical Devices Advisory Committee
(Comprised of 18 Panels)
------------------------------------------------------------------------
Anesthesiology and Respiratory Therapy Date(s), if needed, to be
Devices Panel. determined.
Circulatory System Devices Panel....... May 17, May 24, June 27,
September 27, November 22.
Clinical Chemistry and Clinical April 25.
Toxicology Devices Panel.
Dental Products Panel.................. Date(s), if needed, to be
determined.
Ear, Nose, and Throat Devices Panel.... July 12.
Gastroenterology-Urology Devices Panel. April 24, May 16.
General and Plastic Surgery Devices June 13.
Panel.
General Hospital and Personal Use June 28, August 30.
Devices Panel.
Hematology and Pathology Devices Panel. Date(s), if needed, to be
determined.
Immunology Devices Panel............... Date(s), if needed, to be
determined.
Medical Devices Dispute Resolution Date(s), if needed, to be
Panel. determined.
Microbiology Devices Panel............. June 14.
Molecular and Clinical Genetics Panel.. September 13.
Neurological Devices Panel............. February 22.
Obstetrics and Gynecology Devices Panel September 20.
Ophthalmic Devices Panel............... June 14, August 23.
Orthopaedic and Rehabilitation Devices April 5, September 26.
Panel.
Radiological Devices Panel............. September 12.
Device Good Manufacturing Practice April 11.
Advisory Committee.
National Mammography Quality Assurance October 25.
Advisory Committee.
Technical Electronic Product Radiation Date(s), if needed, to be
Safety Standards Committee. determined.
------------------------------------------------------------------------
CENTER FOR FOOD SAFETY AND APPLIED NUTRITION
------------------------------------------------------------------------
Food Advisory Committee................ July 15-16, August 29-30,
September 23-24.
------------------------------------------------------------------------
CENTER FOR TOBACCO PRODUCTS
------------------------------------------------------------------------
Tobacco Products Scientific Advisory Feb 11-12, April 30-May 1.
Committee.
------------------------------------------------------------------------
CENTER FOR VETERINARY MEDICINE
------------------------------------------------------------------------
Veterinary Medicine Advisory Committee. Date(s), if needed, to be
determined.
------------------------------------------------------------------------
NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH (NCTR)
------------------------------------------------------------------------
Science Advisory Board to NCTR......... December 10-11.
------------------------------------------------------------------------

Dated: December 26, 2012.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2012-31475 Filed 12-31-12; 8:45 am]
BILLING CODE 4160-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.